Share on StockTwits

Sarepta Therapeutics (NASDAQ:SRPT) rose 14.1% on Wednesday after WBB Securites upgraded the stock from a speculative buy rating to a buy rating, StockRatingsNetwork reports. The company traded as high as $23.79 and last traded at $23.20, with a volume of 2,020,454 shares changing hands. The stock had previously closed at $20.33.

Several other analysts have also recently commented on the stock. Analysts at WBB Securities raised their price target on shares of Sarepta Therapeutics to $25.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Bank of America initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, July 22nd. They set a “neutral” rating and a $27.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 15th. They now have a $23.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $38.14.

The stock’s 50-day moving average is $26.9 and its 200-day moving average is $28.30. The company’s market cap is $938.4 million.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.75) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.80) by $0.05. The company had revenue of $6.09 million for the quarter, compared to the consensus estimate of $3.45 million. During the same quarter in the prior year, the company posted ($0.41) earnings per share. The company’s quarterly revenue was up 36.0% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutics will post $-3.10 earnings per share for the current fiscal year.

Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.